Yong-Ping Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Yong-Ping Chen has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Ming-Hua Zheng
MAFLD Research Center, Department of Hepatology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China
8 shared publications - Ke-Qing Shi
Translational Medicine Laboratory, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China
3 shared publications - Yu-Chen Fan
Department of Hepatology, Qilu Hospital of Shandong University, Jinan, China
3 shared publications - Dongdong Xiao
Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine Baoshan Branch, No.160 Pujian Road, Shanghai 200127, China, Shanghai, Shanghai, 200044, China
2 shared publications Lei Zhang
Department of Infection and Liver Diseases, The First Affiliated Hospital of Wenzhou Medical College, Wenzhou, China
2 shared publicationsM.‐M. Peng
Department of Infection and Liver Diseases, Liver Research Center, the First Affiliated Hospital of Wenzhou Medical College, Wenzhou, China
2 shared publications
Latest Publications
- 17 November 2011
- Published by Wiley in Journal of Viral Hepatitis
- Vol. 19 (2) , E66-E72
Tumour necrosis factor‐α‐857T allele reduces the risk of hepatitis B virus infection in an Asian population
Summary. Tumour necrosis factor‐α (TNF‐α) plays a pivotal role in hepatitis B virus (HBV) clearance and host immune response determining the chronicity of HBV infection. However, studies of the association between TNF‐α‐857 polymorphism and chronic HBV infection have reported conflicting results. So a meta‐analysis was carried out to draw a more precise conclusion. Pubmed (January, 1966–March, 2011) and the China Biological Medicine Database (January, 1978–March, 2011) were searched using the keywords TNF‐α gene polymorphism in combination with HBV infection without language restriction. Fourteen studies including 4929 chronic HBV infection cases and 2702 controls describing the C857T genotype were included in the meta‐analysis. All fourteen studies focussed on an Asian population. The overall meta‐analysis suggested that TNF‐α‐857T allele reduced the risk of chronic HBV infection in the Asian population (OR = 0.82, 95% CI: 0.71–0.95, P = 0.008) when compared with a spontaneously recovered population. In the sensitivity analyses of the groups obeying Hardy–Weinberg equilibrium (HWE), without the largest study population and without the smallest study population, a similar association was revealed (OR = 0.81, 95% CI: 0.68–0.98, P = 0.043; OR = 0.77, 95% CI: 0.68–0.87, P = 0.0001; OR = 0.81, 95% CI: 0.70–0.95, P = 0.009, respectively). However, when compared with a healthy population, no significant association was found in the Asian population in all groups. So, we draw the conclusion that the TNF‐α‐857T allele reduces the risk of chronic HBV infection in this Asian population.
- 17 November 2011
- Published by Wiley in Journal of Viral Hepatitis
- Vol. 19 (2) , E66-E72
Tumour necrosis factor‐α‐857T allele reduces the risk of hepatitis B virus infection in an Asian population
Summary. Tumour necrosis factor‐α (TNF‐α) plays a pivotal role in hepatitis B virus (HBV) clearance and host immune response determining the chronicity of HBV infection. However, studies of the association between TNF‐α‐857 polymorphism and chronic HBV infection have reported conflicting results. So a meta‐analysis was carried out to draw a more precise conclusion. Pubmed (January, 1966–March, 2011) and the China Biological Medicine Database (January, 1978–March, 2011) were searched using the keywords TNF‐α gene polymorphism in combination with HBV infection without language restriction. Fourteen studies including 4929 chronic HBV infection cases and 2702 controls describing the C857T genotype were included in the meta‐analysis. All fourteen studies focussed on an Asian population. The overall meta‐analysis suggested that TNF‐α‐857T allele reduced the risk of chronic HBV infection in the Asian population (OR = 0.82, 95% CI: 0.71–0.95, P = 0.008) when compared with a spontaneously recovered population. In the sensitivity analyses of the groups obeying Hardy–Weinberg equilibrium (HWE), without the largest study population and without the smallest study population, a similar association was revealed (OR = 0.81, 95% CI: 0.68–0.98, P = 0.043; OR = 0.77, 95% CI: 0.68–0.87, P = 0.0001; OR = 0.81, 95% CI: 0.70–0.95, P = 0.009, respectively). However, when compared with a healthy population, no significant association was found in the Asian population in all groups. So, we draw the conclusion that the TNF‐α‐857T allele reduces the risk of chronic HBV infection in this Asian population.
- 22 July 2011
- Published by Wiley in Journal of Viral Hepatitis
- Vol. 19 (2) , E11-E17
The tumour necrosis factor‐α‐238A allele increases the risk of chronic HBV infection in European populations
Summary. Tumour necrosis factor‐α (TNF‐α) plays a pivotal role in viral clearance and host immune response to hepatitis B virus (HBV) infection, of which the production capacity in individuals is demonstrated to be influenced by a single nucleotide polymorphism within the promoter region of TNF‐α genes. However, there have been conflicting results reported in previous studies on TNF‐α‐238 and TNF‐α‐863 gene promoter polymorphisms in chronic HBV infection. To derive a more precise estimation of their relationship, we searched Pubmed (January, 1966–August, 2010) and China Biological Medicine Database (January, 1978–August, 2010) and carried out a meta‐analysis involving nineteen studies that included 5245 chronic HBV infection cases and 3181 controls describing G238A genotypes, and eleven studies totalling 3576 cases and 2044 controls describing C863A genotypes. The overall meta‐analysis did not suggest significant associations of TNF‐α‐238 and TNF‐α‐863 gene promoter polymorphisms with chronic HBV infection. However, in subgroup analysis by ethnicity, it indicated that TNF‐α‐238A allele carriers (GA + AA) in European populations had an increased risk of developing chronic HBV infection (OR = 2.22, 95% CI: 1.07–4.58, P = 0.032; OR = 4.46, 95% CI: 1.75–11.38, P = 0.002, respectively), when compared with spontaneous recovered and healthy populations, respectively. However, no significant associations were found in Asian populations in all genetic models. So, we draw the conclusion that the TNF‐α‐238A allele may increase the risk of chronic HBV infection in European populations.
- 22 July 2011
- Published by Wiley in Journal of Viral Hepatitis
- Vol. 19 (2) , E11-E17
The tumour necrosis factor‐α‐238A allele increases the risk of chronic HBV infection in European populations
Summary. Tumour necrosis factor‐α (TNF‐α) plays a pivotal role in viral clearance and host immune response to hepatitis B virus (HBV) infection, of which the production capacity in individuals is demonstrated to be influenced by a single nucleotide polymorphism within the promoter region of TNF‐α genes. However, there have been conflicting results reported in previous studies on TNF‐α‐238 and TNF‐α‐863 gene promoter polymorphisms in chronic HBV infection. To derive a more precise estimation of their relationship, we searched Pubmed (January, 1966–August, 2010) and China Biological Medicine Database (January, 1978–August, 2010) and carried out a meta‐analysis involving nineteen studies that included 5245 chronic HBV infection cases and 3181 controls describing G238A genotypes, and eleven studies totalling 3576 cases and 2044 controls describing C863A genotypes. The overall meta‐analysis did not suggest significant associations of TNF‐α‐238 and TNF‐α‐863 gene promoter polymorphisms with chronic HBV infection. However, in subgroup analysis by ethnicity, it indicated that TNF‐α‐238A allele carriers (GA + AA) in European populations had an increased risk of developing chronic HBV infection (OR = 2.22, 95% CI: 1.07–4.58, P = 0.032; OR = 4.46, 95% CI: 1.75–11.38, P = 0.002, respectively), when compared with spontaneous recovered and healthy populations, respectively. However, no significant associations were found in Asian populations in all genetic models. So, we draw the conclusion that the TNF‐α‐238A allele may increase the risk of chronic HBV infection in European populations.
- 1 April 2011
- Published by Elsevier in Clinical Gastroenterology and Hepatology
- Vol. 9 (4) , 351-356.e3
A Model to Determine 3-Month Mortality Risk in Patients With Acute-on-Chronic Hepatitis B Liver Failure
- 1 April 2011
- Published by Elsevier in Clinical Gastroenterology and Hepatology
- Vol. 9 (4) , 351-356.e3
A Model to Determine 3-Month Mortality Risk in Patients With Acute-on-Chronic Hepatitis B Liver Failure
- 1 April 2010
- Published by Elsevier in Clinical Therapeutics
- Vol. 32 (4) , 649-658
A 24-week, parallel-group, open-label, randomized clinical trial comparing the early antiviral efficacy of telbivudine and entecavir in the treatment of hepatitis B e antigen-positive chronic hepatitis B virus infection in adult Chinese patients
- 1 April 2010
- Published by Elsevier in Clinical Therapeutics
- Vol. 32 (4) , 649-658
A 24-week, parallel-group, open-label, randomized clinical trial comparing the early antiviral efficacy of telbivudine and entecavir in the treatment of hepatitis B e antigen-positive chronic hepatitis B virus infection in adult Chinese patients
- 31 August 2009
- Published by Elsevier in Current Therapeutic Research
- Vol. 70 (4) , 323-334
Effectiveness and tolerability of NSAIDs in the prophylaxis of pancreatitis after endoscopic retrograde cholangiopancreatography: A systematic review and meta-analysis
- 31 August 2009
- Published by Elsevier in Current Therapeutic Research
- Vol. 70 (4) , 323-334
Effectiveness and tolerability of NSAIDs in the prophylaxis of pancreatitis after endoscopic retrograde cholangiopancreatography: A systematic review and meta-analysis
- 1 January 2009
- Published by Elsevier in Cytotherapy
- Vol. 11 (3) , 326-329
Mixed microencapsulation of rat primary hepatocytes and Sertoli cells improves the metabolic function in a D-galactosamine and lipopolysaccharide-induced rat model of acute liver failure
Hepatocyte transplantation is an alternative to transplantation of the whole liver. Compared with xenogeneic hepatocytes, primary hepatocytes have some advantages, such as a more powerful function and a smaller frequency of rejection caused by the host. Cell microencapsulation prevents direct access of host cells to the graft but cannot impede transfer of transplant-derived peptides, which can cross the physical barrier. Sertoli cells are central to the immune privilege demonstrated in the testis, and their actions have been utilized to protect cell transplants. Co-microencapsulating Sertoli cells with HepG2 cells has proved to be a valuable strategy in hepatocyte transplantation. Thus mixed microcapsules of primary rat hepatocytes and primary Sertoli cells may improve metabolic function in a d-galactosamine and lipopolysaccharide-induced rat model of acute liver failure.
- 1 January 2009
- Published by Elsevier in Cytotherapy
- Vol. 11 (3) , 326-329
Mixed microencapsulation of rat primary hepatocytes and Sertoli cells improves the metabolic function in a D-galactosamine and lipopolysaccharide-induced rat model of acute liver failure
Hepatocyte transplantation is an alternative to transplantation of the whole liver. Compared with xenogeneic hepatocytes, primary hepatocytes have some advantages, such as a more powerful function and a smaller frequency of rejection caused by the host. Cell microencapsulation prevents direct access of host cells to the graft but cannot impede transfer of transplant-derived peptides, which can cross the physical barrier. Sertoli cells are central to the immune privilege demonstrated in the testis, and their actions have been utilized to protect cell transplants. Co-microencapsulating Sertoli cells with HepG2 cells has proved to be a valuable strategy in hepatocyte transplantation. Thus mixed microcapsules of primary rat hepatocytes and primary Sertoli cells may improve metabolic function in a d-galactosamine and lipopolysaccharide-induced rat model of acute liver failure.
- Open Access
- 1 January 2009
- Published by Elmer Press, Inc. in Journal of Clinical Medicine Research
- Vol. 1 (1) , 13-16-6
Hepatoblastoma in Adult: Review of the Literature
This study is to review and retrieve data on adult hepatoblastoma (HB) from English literatures in order to gain a better understanding of this disease. We performed Medline, PubMed (from January 1966 to February 2008), and library searches (National Science and Technology Library, Beijing, China, and Wenzhou Medical College Library, from January 1980 to February 2008) using the key words hepatoblastoma in adult, hepatic tumor, hepatoblastoma and adult. Previously reported HB cases were collected and published reviews were also examined. Fifteen cases that met the search criteria were selected. Review of the cases revealed a slight female preponderance. The patients’ age ranged from 17 to 82, with median age of 70 for male and 27 for female. The survival time ranged from two weeks to 38 months, and the median survival time was 6 months. In the articles reviewed, HB presented with non-specific initial symptoms, and the diagnosis was not identified until the tumor biopsy after operation or autopsy. Completely surgical resection is still the major treatment for patients with HB and is considered as the only chance of a better prognosis. Due to the rareness of HB in adults, the choice of treatment should be radical resection if possible, and combined with chemotherapy as adopted in children. HB in the adult is extremely rare and the pre-operative diagnosis is often overlooked. The prognosis is so poor that the awareness of the condition in the differential diagnosis in liver tumors could be beneficial. doi:10.4021/jocmr2009.01.1222
- 1 January 2009
- Published by Elmer Press, Inc. in Journal of Clinical Medicine Research
- Vol. 1 (1) , 13-16-6
Open AccessHepatoblastoma in Adult: Review of the Literature
This study is to review and retrieve data on adult hepatoblastoma (HB) from English literatures in order to gain a better understanding of this disease. We performed Medline, PubMed (from January 1966 to February 2008), and library searches (National Science and Technology Library, Beijing, China, and Wenzhou Medical College Library, from January 1980 to February 2008) using the key words hepatoblastoma in adult, hepatic tumor, hepatoblastoma and adult. Previously reported HB cases were collected and published reviews were also examined. Fifteen cases that met the search criteria were selected. Review of the cases revealed a slight female preponderance. The patients’ age ranged from 17 to 82, with median age of 70 for male and 27 for female. The survival time ranged from two weeks to 38 months, and the median survival time was 6 months. In the articles reviewed, HB presented with non-specific initial symptoms, and the diagnosis was not identified until the tumor biopsy after operation or autopsy. Completely surgical resection is still the major treatment for patients with HB and is considered as the only chance of a better prognosis. Due to the rareness of HB in adults, the choice of treatment should be radical resection if possible, and combined with chemotherapy as adopted in children. HB in the adult is extremely rare and the pre-operative diagnosis is often overlooked. The prognosis is so poor that the awareness of the condition in the differential diagnosis in liver tumors could be beneficial. doi:10.4021/jocmr2009.01.1222
- 1 August 2008
- Published by Elsevier in Current Therapeutic Research
- Vol. 69 (4) , 288-304
Gabexate mesylate in the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: A systematic review and meta-analysis update
- 1 August 2008
- Published by Elsevier in Current Therapeutic Research
- Vol. 69 (4) , 288-304
Gabexate mesylate in the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: A systematic review and meta-analysis update